Cryoport reported a 16% year-over-year revenue increase to $47.8 million in Q1 2026, driven by strong growth in commercial cell and gene therapy (CGT) revenue, which rose 26% to $9.1 million. Life Sciences Services and Products segments also grew, supporting 766 global clinical trials and 21 approved CGTs. The company raised its full-year revenue guidance to $192-$196 million, citing ongoing expansion and new supply chain centers opening in Paris and California later this year. This positions Cryoport for continued growth in the life sciences temperature-controlled supply chain market.
BlackRock, Inc. has reported that its direct and indirect ownership in Orion Oyj has dropped below the 5% threshold as of June 15, 2026. This change requires a formal disclosure under Finnish securities law. The reduction in BlackRock's stake may aff...
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
US stock futures showed mixed results with the S&P 500 slightly down while the Dow Jones and Nasdaq 100 edged higher following a recent rally. The market reacted to a preliminary US-Iran agreement aimed at extending a ceasefire and reopening the Stra...
MindWalk Holdings Corp. emphasizes the importance of a connected, trustworthy biological data layer over AI model size in drug discovery. The company launched ReefIQ™, a biological context layer, and LensAI™, a reasoning platform, aiming to reduce co...
Space Exploration Technologies Corp. (SpaceX) saw its shares surge over 11% in premarket trading, pushing its market capitalization close to $3 trillion, surpassing Amazon to become the fifth-largest company globally. This rapid valuation increase ha...
